SPCR Rapid Response impacts & outputs
SPCR Funded COVID-19 research updates
The SPCR ran a rapid response funding round this time last year, to better understand the virus, its epidemiology, its management, and its consequences for health care delivery.
Rapid COVID-19 Intelligence to improve primary care response (RAPCI)
The University of Bristol's RAPCI trial has drawn public attention for the summary reports and publications highlighting the primary care response to the pandemic. The project identified the changing demands on GP practices across Bristol, North Somerset and South Gloucestershire during the COVID-19 pandemic. Researchers investigated the common challenges and innovative solutions that practices came up with. The media releases and news can be found on the RAPCI website: Rapid COVID-19 Intelligence to improve primary care response (RAPCI). (Murphy, Horwood, Salisbury, MacLeod, Denholm).
Case Study: Coping with the rapid shift to remote GP consultations during the coronavirus pandemic
ACE- Inhibitors/Angiotensin Receptor Blockers and risk of death for people infected with COVID-19
Researchers investigated the use of ACE-Inhibitors and the risk of death for people infected with COVID-19. The research aimed to study the link between taking ACE-I/ARB medications and the risk of death in people infected with COVID-19. View the SPCR case study ACE-Inhibitors/Angiotensin Receptor Blockers and risk of death for people infected with COVID-19.
Team: Hajira Dambha-Miller, Simon de Lusignan, Julia Hippisley-Cox, Paul Little, Simon J Griffin, Ali Albasri, Beth Stuart, William Hinton.
RAPTOR C19
The RAPTOR C19 study assesses the accuracy of different rapid tests for COVID-19 for patients in the community. The study, working across 26 GP surgeries and community 'hot hubs', aims to determine whether rapid tests, which give results within minutes/hours, are as accurate as standard laboratory tests. RAPTOR C19 is part of the CONDOR diagnostic evaluation platform which is accelerating how quickly COVID-19 diagnostics make it into real-world use. Partners of the platform include Manchester NHS Foundation Trust's Diagnostic Technology Accelerator (DiTA), and NIHR MedTech and In Vitro Diagnostics Co-operatives (MICs) based in Oxford, Leeds, London and Newcastle.
Team: Brian, Nicholson, Richard Hobbs, Simon de Lusignan, Uy Hoang, Filipa Fereira, Alex Deeks, Harshana Liyananga, Gail Hayward, Philip Turner, Joseph Lee, Tom Fanshawe and Jason Oke.
LOngitudinal study of behaviours, risk factors, and effects of COVID-19 in the Community (LOCC)
LOngitudinal study of behaviours, risk factors, and effects of COVID-19 in the Community (LOCC) produced rapid analyses from information collected from people in the community who do, and do not, have symptoms suggestive of COVID-19. This will help policymakers, clinicians and the public make more informed decisions about how best to manage the ongoing pandemic clinically, psychologically and socially.
Team: Nick Francis (PI), Merlin Willcox, Paul Little, Alastair Hay, Michael Moore, Mark Lown, Beth Stuart, Jennifer Bostock, Judy Chatwin, Adam Geraghty, Lucy Yardley.
Optimising the telephone management of people affected or at risk of COVID-19 infection via NHS111 services
Optimising the telephone management of people affected or at risk of COVID-19 infection via NHS 111 services aims to learn how the NHS 111 are currently advising the public about what to do about coronavirus and inform how they can best deliver services in the future.
Team: Rebecca Barnes, Geraldine Leydon, Catherine Pope, Catherine Woods, Jennie Hayes, Lydia Holt, Charlotte Albury
Using linked primary care and viral surveillance data to develop risk stratification models to inform management of severe COVID19
Researchers have joined routine health data recorded by GP surgeries to the records of the most severely ill COVID19 patients who have been admitted to hospital intensive care units. Researchers were then able to find out which existing health problems, drug treatments, or other factors (for example, smoking or pregnancy) are most strongly associated with people being admitted to intensive care or dying as a complication of COVID19.
Team: Rupert Payne, Evan Kontopantelis, Jonathan Mant, Jennifer Denholm, Jennifer Cooper,Harriet Forbes, Annie Herbert, Peter Tammes
COVID-19: Understanding which patients are at the greatest risk of harm
Media coverage:
Epigram: https://epigram.org.uk/2020/05/12/university-of-bristol-researching-covid-19-patients-most-at-risk/
Health Business: https://healthbusinessuk.net/news/11052020/study-which-patients-are-greatest-risk-harm
Mirage News: https://www.miragenews.com/covid-19-understanding-which-patients-are-at-greatest-risk-of-harm/